CAS 500577-51-5

Fórmula: C29H42F3N9O9

InChI: InChI=1S/C27H41N9O7.C2HF3O2/c28-11-5-4-9-18-24(41)34-17(10-6-12-31-27(29)30)23(40)32-15-21(37)33-20(14-22(38)39)26(43)36-19(25(42)35-18)13-16-7-2-1-3-8-16;3-2(4,5)1(6)7/h1-3,7-8,17-20H,4-6,9-15,28H2,(H,32,40)(H,33,37)(H,34,41)(H,35,42)(H,36,43)(H,38,39)(H4,29,30,31);(H,6,7)/t17-,18-,19+,20-;/m0./s1

Clave InChI: WHCQIPJAWCYHFT-HXSCNMCGSA-N

SMILES: C1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CCCCN)CC2=CC=CC=C2)CC(=O)O.C(=O)(C(F)(F)F)O

2-((2S,5R,8S,11S)-8-(4-Aminobutyl)-5-Benzyl-11-(3-Guanidinopropyl)-3,6,9,12,15-Pentaoxo-1,4,7,10,13-Pentaazacyclopentadecan-2-Yl)Acetic Acid Trifluoroacetate

CAS: 500577-51-5

2-((2S,5R,8S,11S)-8-(4-Aminobutyl)-5-Benzyl-11-(3-Guanidinopropyl)-3,6,9,12,15-Pentaoxo-1,4,7,10,13-Pentaazacyclopentadecan-2-Yl)Acetic Acid Trifluoroacetate

Fórmula: C₂₉H₄₂F₃N₉O₉

Pureza: 98%

Peso molecular: 717.69

Ref: 54-PC108413

Cyclo(-RGDfK) TFA

CAS: 500577-51-5

Cyclo(-RGDfK) TFA

Fórmula: C₂₉H₄₂F₃N₉O₉

Pureza: ≥98%

Peso molecular: 717.69

Ref: 54-BUP01160

Cyclo(-RGDfK) TFA

CAS: 500577-51-5

Fórmula: C₂₉H₄₂F₃N₉O₉

Pureza: 98%

Forma y color: Solid

Peso molecular: 717.6939

Ref: IN-DA01EB1F

Cyclo(-RGDfK) TFA

CAS: 500577-51-5

2-((2S,5R,8S,11S)-8-(4-Aminobutyl)-5-benzyl-11-(3-guanidinopropyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid Trifluoroacetate (1:1)

Fórmula: C₂₉H₄₂F₃N₉O₉

Pureza: 98%

Peso molecular: 717.69

Ref: IN-DG764848

Cyclo(-RGDfK) TFA

CAS: 500577-51-5

Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).

Fórmula: C₂₉H₄₂F₃N₉O₉

Pureza: 98.99% - 99.54%

Forma y color: Solid

Peso molecular: 717.69

Ref: TM-T6812L

Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate

CAS: 500577-51-5

Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate is a cyclic peptide that has been shown to be an effective chemotherapeutic agent against bladder cancer. Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate binds to the integrin receptor on the tumor cell surface and blocks the formation of new blood vessels, which may lead to tumor growth inhibition. The hypoxic tumor environment is characterized by low oxygen levels, which causes the mitochondria in cells to produce more hydrogen peroxide. Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate has been shown to decrease the production of hydrogen peroxide in hypoxic tumors. This drug also inhibits angiogenesis and cellular proliferation. Cyclo(-Arg-Gly-Asp) trifluoroacetate has

Fórmula: C₂₇H₄₁N₉O₇•C₂HF₃O₂

Pureza: Min. 98 Area-%

Forma y color: White Off-White Powder

Peso molecular: 717.7 g/mol

Ref: 3D-FC110054